Nuvation Bio Inc.

NUVB NYSE SEC CIK 1811063
Follow Nuvation Bio Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $45M +242.6% vs same quarter last year
Net income −$41.9M +24.9% vs same quarter last year
EPS, diluted −$0.12 +25% vs same quarter last year
Operating cash flow −$38.6M +27.1% vs same quarter last year
Revenue by quarter
$5.7M
$3.1M
$4.8M
$13.1M
$41.9M
$83.2M
$31.7M
$45M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$600M−$400M−$200M$0$200MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$62.9M−$204.6M
FY24$7.9M−$567.9M
FY23$0−$75.8M
FY22-−$104.2M
FY21-−$86.8M
FY20-−$41.7M
FY19--